Navigation Links
AspenBio to Present at 2012 Aegis Healthcare Conference
Date:9/20/2012

CASTLE ROCK, Colo., Sept. 20, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced that it will present at the 2012 Aegis Healthcare Conference to be held September 27 – 29, 2012, at The Wynn in Las Vegas, NV.  

Steve Lundy, President and CEO of AspenBio, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event: 2012 Aegis Healthcare Conference
Date: Friday, September 28, 2012
Time: 9:00 am (Pacific Time)
Location: The Wynn, Las Vegas, NV

About AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its lead product, AppyScoreAppyScore is a unique blood-based test with projected high sensitivity and negative predictive value that is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  AppyScore is initially being developed for pediatric, adolescent and young adult patients with abdominal pain as this population is at the highest risk for appendicitis as well having the highest risk of the long-term health effects associated with CT imaging.  For more information, visit www.aspenbiopharma.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that addres
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AspenBio Announces Dismissal of Class Action and Chipman Lawsuits by U. S. District Court
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
4. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
5. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
6. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
7. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
8. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
9. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
10. PRA Expert to Present at Pharmacovigilance Conference
11. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
(Date:7/25/2014)... AVIV, Israel , July 25, 2014  Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, today announced financial results ... First Half 2014 Financial Summary: , Reported cash ... 2014, compared with $137,000 at December 31, 2013.  ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Lumidigm, Inc. is proud to announce that its ... technologies and products recognized by Popular Science as ... Venus product is the first high-volume multispectral imaging ... ease of integration, the Venus fingerprint sensor features ...
... LAUSANNE, Switzerland and BANGALORE, India, November ... biopharmaceutical development,specialist that focuses on serious ... Discovery Technologies Ltd (Aurigene), a,Bangalore-based fully ... molecule,and peptide drug discovery and development ...
... (OTC Bulletin Board: SYMD) announced today that it has ... membrane intended to prevent post-operative adhesions in nasal and ... and sinus procedures performed annually in the United States. ... P. Hickey, SyntheMed,s President & CEO stated, "SinusShield represents ...
Cached Biology Technology: Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 2 Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 3Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3SyntheMed Announces FDA Clearance of SinusShield(TM) 2
(Date:7/25/2014)... bifda (SB) is a complex congenital central nervous ... closing of the neural tubes during the embryonic ... urinary and fecal incontinence and neurocognitive retardation. Such ... quality of life. Researchers at Ankara Physical Medicine ... the functional performance in children with SB, using ...
(Date:7/25/2014)... first time, Spanish researchers have detected an unknown interaction ... cells are introduced into a droplet of salt water ... chloride crystallisation to create biomineralogical biosaline 3D morphologically complex ... material, bacteria are revived. The discovery was made by ... cover of the Astrobiology journal and may ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... The leaking of environmentally damaging pollutants into our waters ... mathematical algorithm, according to researchers. Presenting their research ... Problems , the researchers, from Universit de Technologie ... avoid environmental catastrophes by identifying the exact location where ...
... renowned biologist and population geneticist, has been named founding ... This newly created position will further strengthen GW,s role ... region and nationally. As director, Dr. Crandall ... Institute and direct the development and implementation of research ...
... as an important predictor of survival among human patients with ... Veterinary Medicine at Tufts University have developed two surveys that ... of life for dogs and cats with heart disease. ... (Cats, Assessment Tool for Cardiac Health), the surveys ask owners ...
Cached Biology News:Maths formula leads researchers to source of pollution 2GW announces creation of Computational Biology Institute to conduct integrated research 2GW announces creation of Computational Biology Institute to conduct integrated research 3GW announces creation of Computational Biology Institute to conduct integrated research 4New tools for evaluating quality of life for cats, dogs with heart disease 2
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... dsRNA Marker consists of ten double-stranded RNAs, ... 400, 500 and 1,000 base pairs. The ... for determinating sizes of double-stranded RNAs. A ... dsRNA Marker is adjusted to approximately 25 ...
... antibody raised against a partial ... Immunogen: HD (NP_002102, 81 ... recombinant protein with GST tag. ... NM_002111 ...
Biology Products: